Dr. Matthew J. Wieduwilt
Claim this profileUniversity of California San Diego
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
7 reported clinical trials
18 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Philadelphia chromosome positive
BCR-ABL1 positive
IDH positive
2Acute Myeloid Leukemia
IDH positive
Affiliated Hospitals
Clinical Trials Matthew J. Wieduwilt is currently running
Acalabrutinib Maintenance
for Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Recruiting1 award Phase 1 & 224 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting1 award Phase 21 criteria
More about Matthew J. Wieduwilt
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Matthew J. Wieduwilt has experience with
- Liposome-encapsulated Daunorubicin-Cytarabine
- Azacitidine
- Venetoclax
- Blinatumomab
- Pembrolizumab
- Enasidenib Mesylate
Breakdown of trials Matthew J. Wieduwilt has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew J. Wieduwilt specialize in?
Matthew J. Wieduwilt focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 positive.
Is Matthew J. Wieduwilt currently recruiting for clinical trials?
Yes, Matthew J. Wieduwilt is currently recruiting for 3 clinical trials in San Diego California. If you're interested in participating, you should apply.
Are there any treatments that Matthew J. Wieduwilt has studied deeply?
Yes, Matthew J. Wieduwilt has studied treatments such as Liposome-encapsulated Daunorubicin-Cytarabine, Azacitidine, Venetoclax.
What is the best way to schedule an appointment with Matthew J. Wieduwilt?
Apply for one of the trials that Matthew J. Wieduwilt is conducting.
What is the office address of Matthew J. Wieduwilt?
The office of Matthew J. Wieduwilt is located at: University of California San Diego, San Diego, California 92103 United States. This is the address for their practice at the University of California San Diego.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.